- Home
- BMRA vs KZIA Comparison
BMRA vs KZIA Comparison
Compare BMRA & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMRA
- KZIA
- Stock Information
- Founded
- BMRA 1971
- KZIA 1994
- Country
- BMRA United States
- KZIA Australia
- Employees
- BMRA N/A
- KZIA N/A
- Industry
- BMRA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- BMRA Health Care
- KZIA Health Care
- Exchange
- BMRA Nasdaq
- KZIA Nasdaq
- Market Cap
- BMRA 8.2M
- KZIA 9.0M
- IPO Year
- BMRA N/A
- KZIA 1999
- Fundamental
- Price
- BMRA N/A
- KZIA $7.12
- Analyst Decision
- BMRA
- KZIA Strong Buy
- Analyst Count
- BMRA 0
- KZIA 3
- Target Price
- BMRA N/A
- KZIA $16.00
- AVG Volume (30 Days)
- BMRA 33.1K
- KZIA 302.5K
- Earning Date
- BMRA 10-10-2025
- KZIA 11-14-2025
- Dividend Yield
- BMRA N/A
- KZIA N/A
- EPS Growth
- BMRA N/A
- KZIA N/A
- EPS
- BMRA N/A
- KZIA N/A
- Revenue
- BMRA $5,311,000.00
- KZIA $1,549,158.00
- Revenue This Year
- BMRA N/A
- KZIA N/A
- Revenue Next Year
- BMRA N/A
- KZIA $49.25
- P/E Ratio
- BMRA N/A
- KZIA N/A
- Revenue Growth
- BMRA N/A
- KZIA 248983.08
- 52 Week Low
- BMRA $2.08
- KZIA $2.86
- 52 Week High
- BMRA $10.16
- KZIA $39.05
- Technical
- Relative Strength Index (RSI)
- BMRA 45.61
- KZIA 44.01
- Support Level
- BMRA $2.68
- KZIA $6.20
- Resistance Level
- BMRA $2.83
- KZIA $8.00
- Average True Range (ATR)
- BMRA 0.11
- KZIA 0.48
- MACD
- BMRA 0.01
- KZIA -0.03
- Stochastic Oscillator
- BMRA 54.84
- KZIA 49.73
About BMRA Biomerica Inc.
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.